TEVATeva Pharmaceutical Industries Limited
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +22% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Lightly shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How TEVA is trading
Teva Pharmaceutical Industries Limited is +124% over the past year while the S&P 500 is +18%: 106 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +22%
vs 200-day average · a clear uptrend
- RSI (14)
- 57
RSI (14) · neutral
- Below its 52-week high
- 0.00%
Below its 52-week high
Details›
- Last close2026-10-09
- $41.07
- 1 monthS&P 500 +2.7%
- +13%
- 1 yearS&P 500 +18%
- +124%
- 5 yearsS&P 500 +88%
- +353%
- vs 50-day average$37.41
- +9.8%
- 52-week high
- $41.07
- 52-week low
- $18.34
- Annualised volatility
- 44%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$23M
| Year | Return |
|---|---|
| 2026 (year to date) | +32% |
| 2025 | +42% |
| 2024 | +111% |
| 2023 | +14% |
| 2022 | +14% |
| 2021 | −17% |
| 2020 | −1.5% |
| 2019 | −36% |
| 2018 | −19% |
| 2017 | −46% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 8 of 10 | +8.3% |
| Feb | 10 | 3 of 10 | −2.4% |
| Mar | 10 | 3 of 10 | −4.4% |
| Apr | 10 | 4 of 10 | +2.1% |
| May | 10 | 6 of 10 | −0.52% |
| Jun | 10 | 4 of 10 | +1.2% |
| Jul | 11 | 4 of 11 | +0.79% |
| Aug | 11 | 4 of 11 | −3.3% |
| Sep | 11 | 5 of 11 | −0.03% |
| Oct | 11 | 5 of 11 | −2.6% |
| Nov | 10 | 6 of 10 | +7.0% |
| Dec | 10 | 6 of 10 | +4.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #14 of 41 by RyuScore